Mesothelioma.com Resources for Patients and their Families

Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma

Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if radiation therapy is effective in preventing metastatic cancer following surgery.

PURPOSE: Randomized phase III trial to determine the effectiveness of radiation therapy in preventing metastatic cancer in patients who have undergone diagnostic procedures to identify malignant mesothelioma.

Tracking Information
First Received DateSeptember 11, 2000
Last Changed DateDecember 18, 2013
Start DateFebruary 1998
Primary Outcome Measures

Incidence of metastatic skin nodules

Descriptive Information
PhasePhase 3
Study TypeInterventional
Condition
  • Malignant Mesothelioma
  • Perioperative/Postoperative Complications
Intervention
  • Procedure: quality-of-life assessment
  • Procedure: standard follow-up care
  • Radiation: radiation therapy
Detailed Description

OBJECTIVES:

- Determine the efficacy of radiotherapy in the prevention of metastatic skin nodules or tumor seeding following invasive diagnostic procedures, such as chest drain insertion, pleural aspiration, pleural biopsy, and thoracoscopy, in patients with malignant mesothelioma.

- Determine whether the nodules that develop after radiotherapy are symptomatic in these patients.

- Compare the quality of life of patients treated with radiotherapy vs standard care alone.

OUTLINE: This is a randomized study.

Patients are randomized to 1 of 2 treatment arms.

- Arm I: Patients receive radiotherapy on 3 consecutive days beginning within 3 weeks after chest drain insertion, pleural aspiration, pleural biopsy, or thoracoscopy and once the wounds have healed.

- Arm II: Patients receive standard supportive care alone. Quality of life is assessed at baseline, and then at 1, 2, 4, 6, 9, and 12 months.

Patients are followed at 1, 2, 4, 6, 9, and 12 months.

PROJECTED ACCRUAL: A total of 44 patients (22 per arm) will be accrued for this study within 2 years.

Recruitment Information
Recruitment StatusCompleted
Anticipated Enrollment44
GenderAll
AgesN/A - N/A
Accepts Healthy VolunteersNo
Eligibility Criteria

DISEASE CHARACTERISTICS:

- Histologically proven malignant pleural mesothelioma by chest drain insertion, pleural aspiration, pleural biopsy, and/or thoracoscopy within the past 3 weeks

PATIENT CHARACTERISTICS:

Age:

- Not specified

Performance status:

- Not specified

Life expectancy:

- At least 3 months

Hematopoietic:

- Not specified

Hepatic:

- Not specified

Renal:

- Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- No prior systemic chemotherapy for malignant mesothelioma

Endocrine therapy:

- Not specified

Radiotherapy:

- No prior local radiotherapy for malignant mesothelioma

Surgery:

- See Disease Characteristics

- No other invasive procedures to the same chest site during and for 1 year after study

Administrative Information
NCTIDNCT00006231
SponsorUniversity of Glasgow
Verification DateOctober 2000
Mesothelioma Doctors by State
  • Breaking News
  • Emerging Clinical Trials
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog

FEATURED CONTENT:


RECENT POSTS:

High Cost of Asbestos Abatement Leaves Lower Income Communities at Risk

Staying Safe from Asbestos After Natural Disasters

Steve McQueen and Mesothelioma: An Actor and Veteran’s Last Battle

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: